Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Agios Pharmaceuticals Inc
CEO
Mr. Brian M. Goff M.B.A.
Employees
390
Industry
Biotechnology
Sector
Healthcare
Market cap
$2B
Company details
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
NI
Revenue (Rev)
$31.31M
Cost of goods (CoG)
-$3.34M
Gross profit (GP)
$27.96M
Operating expense (OE)
-$433.03M
Research and development (R&D)
-$305.35M
General and administrative (G&A)
-$127.68M
Operating income (OI)
-$405.06M
Other income expense (OIE)
-$6.12M
Pretax income (PI)
-$364.93M
Net income (NI)
-$364.93M
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$6.25
Margin profit
89.26%
52 week low
$20.00
52 week high
$50.610001
50-day simple moving average
$41.80
200-day simple moving average
$42.12
Percent held by insiders
1.55%
Percent held by institutions
104.08%
Dividend yield
0.00%
